For the quarter ended June 2025, Revvity (RVTY) reported revenue of $720.28 million, up 4.1% over the same period last year. EPS came in at $1.18, compared to $1.22 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $711.27 million, representing a surprise of +1.27%. The company delivered an EPS surprise of +3.51%, with the consensus EPS estimate being $1.14.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Revvity performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic revenue growth - Total: 3% versus the four-analyst average estimate of 3.1%.
- Organic revenue growth - Life Sciences: 4% compared to the 2.2% average estimate based on three analysts.
- Organic revenue growth - Diagnostics: 2% compared to the 3.8% average estimate based on three analysts.
- Net Sales- Life Sciences: $365.9 million versus the three-analyst average estimate of $342.32 million. The reported number represents a year-over-year change of +16.6%.
- Net Sales- Diagnostics: $354.39 million versus the three-analyst average estimate of $365.99 million. The reported number represents a year-over-year change of -6.3%.
View all Key Company Metrics for Revvity here>>>
Shares of Revvity have returned +6% over the past month versus the Zacks S&P 500 composite's +4.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Revvity Inc. (RVTY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
